stockrow
Friday 6 November 2026
Export APLM’s income statement to Excel — free account
Apollomics Inc.
APLM Healthcare Biotechnology
Apollomics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 million, up 470.9% from fiscal 2024.
19.00
2.02
+11.90%
Follow APLM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 2 | 1 | 1 | 1 | 1 | 9 | +32.8% | — | — | — | — | |
| Gross margin, % | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | (75) | (95) | (241) | (173) | (54) | (11) | (31.9%) | ||||||
| EBT margin, % | — | — | — | — | (3,636.17) | (8,993.93) | (16,642.02) | (14,181.68) | (3,599.66) | (128.66) | +3,507.5 pt | ||||||
| Net income | — | 0 | — | — | (75) | (95) | (241) | (173) | (54) | (11) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.57 | 0.26 | 5.07 | 1.64 | 1.46 | 5.88 | +59.5% | |||||
| Earnings | — | — | — | — | (20.70) | (23.45) | (844.12) | (232.00) | (52.80) | (7.57) | (18.2%) | ||||||
| Cash flow | — | — | — | — | (9.87) | (10.72) | (150.10) | (58.08) | (28.18) | (7.17) | (6.2%) | ||||||
| Capex | — | — | — | — | (2.81) | (1.87) | (1.29) | 0.07 | (0.02) | 0.03 | n/m | ||||||
| Free cash flow | — | — | — | — | (12.68) | (12.58) | (151.39) | (58.01) | (28.20) | (7.14) | (10.9%) | ||||||
| Book value | — | — | — | — | (35.39) | (52.66) | (1,570.70) | 55.42 | 4.77 | (2.20) | (42.6%) | ||||||
| Shares, m | — | — | — | — | 4 | 4 | 0 | 1 | 1 | 1 | (16.7%) | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | 0.00 | 0.00 | 0.81 | 0.30 | 0.06 | 0.00 | 0.2 | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (36) | (43) | (43) | (43) | (29) | (10) | (21.9%) | |||||
| Capex | — | — | — | — | (10) | (8) | 0 | 0 | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | (46) | (51) | (43) | (43) | (29) | (10) | (25.8%) | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 146 | 86 | 43 | 26 | 3 | 0 | n/m | |||||
| Net debt | — | — | — | — | (154) | (70) | (52) | (34) | (10) | (3) | (53.7%) | ||||||
| Shareholders’ equity | — | — | — | — | (128) | (213) | (448) | 41 | 5 | (3) | (52.2%) | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | (88.05) | (64.62) | (240.92) | (261.79) | (157.28) | (110.43) | (22.4) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (415.11) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | 0.00 | 55.63 | 72.86 | 84.84 | (233.67) | (1,305.45) | (1,305.4) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | 45 | 23 | 45 | 13 | 14 | (25.3%) | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.02 | 0.06 | 0.03 | 0.11 | 0.61 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · fundamentals updated 1 Oct 2026
Apollomics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ELOX Senesco Technologies Inc. | $51.7M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $51.6M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| INKT MiNK Therapeutics, Inc. | $51.3M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OSTX OS Therapies Incorporated | $51.3M | — (loss-making) | — | — | n/m | −134.43% (below 0%: shrinking) | — | 0.00% | Compare |
| PLRX Pliant Therapeutics, Inc. | $50.5M | — (loss-making) | — (loss-making) | −95.03% (below 0%: shrinking) | n/m | +68.61% (above 0%: growing) | 0.00% | 0.00% | Compare |
| HOWL Werewolf Therapeutics, Inc. | $49.6M | — (loss-making) | — (loss-making) | +256.11% (above 0%: growing) | n/m | +146.46% (above 0%: growing) | 100.00% | 34.09% | Compare |
| APLM Apollomics Inc. | $49.5M | — (loss-making) | — | — | 0.00% | +76.08% (above 0%: growing) | — | — | |
| TIL Instil Bio, Inc. | $47.4M | — (loss-making) | — | — | n/m | +68.62% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IMA ImageneBio, Inc. | $47.3M | — (loss-making) | — (loss-making) | −60.08% (below 0%: shrinking) | n/m | +23.76% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $50.9M | — | — | −60.08% | — | +17.84% | 0.00% | 0.00% |